Ratings Eli Lilly and Company

Equities

LLY

US5324571083

Market Closed - Nyse Other stock markets 04:00:02 2023-12-06 pm EST			5-day change	1st Jan Change
589.25 ^USD	+0.19%		-0.44%	+61.07%

Dec. 06	Berenberg: Novo Nordisk Faces Challenging Momentum Picture as Rivals Bite into Obesity Market	MT
Dec. 05	Sector Update: Health Care Stocks Ease Late Afternoon	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
The company's profit outlook over the next few years is a strong asset.
Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Sales forecast by analysts have been recently revised upwards.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Over the past four months, analysts' average price target has been revised upwards significantly.

Weaknesses

With an expected P/E ratio at 98.95 and 48.31 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
Based on current prices, the company has particularly high valuation levels.
The company appears highly valued given the size of its balance sheet.
The valuation of the company is particularly high given the cash flows generated by its activity.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector : Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
ELI LILLY AND COMPANY	+61.07%	530 B $	C+
NOVO NORDISK A/S	+43.28%	438 B $	B
JOHNSON & JOHNSON	-11.34%	377 B $	C+
MERCK & CO., INC.	-4.79%	268 B $	B-
ABBVIE INC.	-9.42%	258 B $	C+
NOVARTIS AG	+0.75%	200 B $	B-
ASTRAZENECA PLC	-9.89%	198 B $	B+
PFIZER, INC.	-43.81%	163 B $	C+
AMGEN INC.	+2.55%	144 B $	C+
SANOFI	-4.85%	117 B $	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes